Portal de Periódicos da CAPES

Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer

2023; Elsevier BV; Volume: 35; Issue: 1 Linguagem: Inglês

10.1016/j.annonc.2023.09.3116

1569-8041

James W.F. Catto, Ben Tran, Morgan Rouprêt, Juergen E. Gschwend, Yohann Loriot, Hiroyuki Nishiyama, Juan Palou Redorta, Siamak Daneshmand, Syed A. Hussain, Hernán Cutuli, Giuseppe Procopio, Valentina Guadalupi, Nikhil Vasdev, Vahid Naini, Lowell T. Crow, Spyros Triantos, Mahadi Baig, Gregory R. Steinberg, Rubén H. Bengió, Hernán Cutuli, Jorge Salinas, Filip Ameye, Steven Joniau, Diogo Rodrigues da Rosa, Karine Martins da Trindade, Murilo Almeida Luz, Mário Henrique Bueno Bavaresco, Adriano de Paula, Jose Santiag, Shaogang Wang, Dingwei Ye, Martin Boegemann, Florian Roghmann, Albert Heidrich, Eva Hellmis, Óscar Rodriguez Faba, José Luis Domínguez, Romain Mathiéu, Marc Colombel, Franck Bladou, Xavier Artignan, Nikhil Vasdev, Rajendra Shimpi, Valentina Guadalupi, Rosa Tambaro, Zuzana Sirotovà, Massimiliano Spada, Andrea Necchi, Hiroomi Nakatsu, Eiji Kikuchi, Nobuaki Shimizu, Kent Kanao, Makoto Sumitomo, Yushi Naito, Won Sik Ham, Seung-Il Jung, H.K. Ha, Kwan Joong Joo, Ja Hyeon Ku, Ho Kyung Seo, Seok Joong Yun, Anna Kołodziej, Janusz Ławiński, David Morris, Siamak Daneshmand, Badar M. Mian, Eugene Lee,

Epigenetics and DNA Methylation

Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette-Guérin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations are commonly detected in NMIBC. We evaluated the activity of oral erdafitinib, a selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy in patients with high-risk NMIBC and select FGFR3/2 alterations following recurrence after BCG treatment.